The results of phase III clinical evaluations of MS209 for breast cancer treatment showed a relative improvement and increased response rate in patients who received MS209 plus cyclophosphamide, doxorubicin, and fluorouracil (CAF); however, differences did not reach statistical significance.
← all excerpts
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
1
—
—